$NBIO Nascent Biotech Receives an Analyst Opinion Suggesting that of the Company is Significantly Under Valued Marble Arch Research suggests Nascent Value at $0.60 to $2.84 per share The report can be viewed on the Company web site at: https://nascentbiotech.com/marble-arch-research-what-is-pritumumab-and-how-it-works/